[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608820":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":43,"locations":48,"responsibleParty":72,"collaborators":74,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":81,"sex":87,"minAge":88,"maxAge":29,"enrollmentInfo":89,"targetDuration":29,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":101,"overallStatus":50,"whyStopped":29,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":117},{"fullName":5,"class":6},"Universitair Ziekenhuis Brussel","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Acetic acid dialysate (0.5 mmol\u002FL Mg)","ACTIVE_COMPARATOR","Standardized hemodialysis treatments 3x4hours\u002Fweek. Intervention: 2 weeks (six hemodialysis sessions) during which patients will be dialyzed with standard acetate-based dialysate containing 0,5 mmol\u002FL magnesium.",[13],"Other: Hemodialysis using acetic acid dialysate with magnesium 0.5 mmol\u002FL",{"label":15,"type":10,"description":16,"interventionNames":17},"Citric acid dialysate (Mg 1.0 mmol\u002FL)","Standardized hemodialysis treatments 3x4hours\u002Fweek. Intervention: 2 weeks (six hemodialysis sessions) using a citric acid dialysate containing magnesium 1.0 mmol\u002FL",[18],"Other: Hemodialysis using dialysate containing citric acid and magnesium at a concentration of 1.0 mmol\u002FL",{"label":20,"type":10,"description":21,"interventionNames":22},"Citric acid dialysate (Mg 0.75 mmol\u002FL)","Standardized hemodialysis treatments 3x4hours\u002Fweek. Intervention: 2 weeks (six hemodialysis sessions) using a citrate-enriched dialysate containing magnesium 0.75 mmol\u002FL",[23],"Other: Hemodialysis using citric acid dialysate with magnesium 0.75 mmol\u002FL",[25,30,34],{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Hemodialysis using dialysate containing citric acid and magnesium at a concentration of 1.0 mmol\u002FL","Change dialysate compositions being used during hemodialysis treatment in each arm.",[15],null,{"type":6,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Hemodialysis using acetic acid dialysate with magnesium 0.5 mmol\u002FL","Standard dialysate containing acetic acid and magnesium at a concentration of 0.5 mmol\u002FL, used during hemodialysis sessions.",[9],{"type":6,"name":35,"description":36,"armGroupLabels":37,"otherNames":29},"Hemodialysis using citric acid dialysate with magnesium 0.75 mmol\u002FL","Dialysate containing citric acid and magnesium at a concentration of 0.75 mmol\u002FL, used during hemodialysis sessions.",[20],[39],{"name":40,"affiliation":41,"role":42},"Florine Janssens, Medical doctor","(1)Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. (2) Kidney diseases, dialysis & transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB)","PRINCIPAL_INVESTIGATOR",[44],{"name":40,"role":45,"phone":46,"phoneExt":29,"email":47},"CONTACT","+324749435","florine.janssens@uzbrussel.be",[49],{"facility":5,"status":50,"city":51,"state":29,"zip":52,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"RECRUITING","Brussels","1090","Belgium","BE",{"type":56,"coordinates":57},"Point",[58,59],4.34878,50.85045,{"lat":59,"lon":58},[62,64,68,69],{"name":40,"role":45,"phone":63,"phoneExt":29,"email":47},"+3224749435",{"name":65,"role":45,"phone":66,"phoneExt":29,"email":67},"Nathalie Marmitte, Study coordinator","+322477 6224","studiesnefrologie@uzbrussel.be",{"name":40,"role":42,"phone":29,"phoneExt":29,"email":29},{"name":70,"role":71,"phone":29,"phoneExt":29,"email":29},"Karlien François, Medical doctor, PhD","SUB_INVESTIGATOR",{"type":73,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR",[75,77],{"name":76,"class":6},"University of Rochester",{"name":78,"class":6},"Vrije Universiteit Brussel","100608820","effect-of-modifying-magnesium-concentration-in-citrate-enriched-dialysate-on-hemodialysis-associated-thromboinflammation-100608820",false,"NCT07206524","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation","Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation: a Local Pilot OMAGOD Plus Trial","pilot OMAGOD +","Inclusion Criteria:\n\n* Participants to the OMAGOD pilot trial\n\nExclusion Criteria:\n\n* Patients who are not participating in the OMAGOD pilot trial","ALL","18 Years",{"count":90,"type":91},15,"ESTIMATED","INTERVENTIONAL",[94],"NA","This clinical trial investigates whether the composition of dialysate influences hemodialysis-associated thromboinflammation. Specifically, it evaluates the effects of magnesium concentration and acid type in dialysate on immune cell activation and thromboinflammatory responses.\n\nPatients participating to the multicentric pilot OMAGOD trial will be invited to participate to this monocentric plus study.\n\nIn the pilot OMAGOD trial, participants will undergo standard hemodialysis (3 sessions\u002Fweek, 4 hours each) and receive three different dialysate compositions in a crossover design. Each treatment phase lasts two weeks (six sessions).\n\nFor the local plus study, during selected sessions (3 per patient - midweek hemodialysis session of the last week of a treatment period), blood samples will be collected (at baseline, hourly, and at the end of dialysis) and additionally, after each session, the used dialysis circuit will be rinsed to recover adherent cells.\n\nThe study aims to:\n\n* Assess whether the dialysate composition influences leukocyte and platelet activation .\n* Evaluate whether the dialysate composition influences neutrophil extracellular trap (NET) formation.\n* Identify novel biomarkers of thromboinflammation using transcriptomic analysis of immune cells.",[97,98,99,100],"Hemodialysis","Thromboinflammation","Hemodialysis Complication","End Stage Renal Disease (ESRD)",[102,103,104,105,106,107],"hemodialysis","thromboinflammation","neutrophil extracellular trap formation","dialysate composition","cellular activation","transcriptome analysis","2025-11-14",{"date":110,"type":111},"2025-11-17","ACTUAL",{"date":113,"type":111},"2025-06-05",{"date":115,"type":91},"2026-12",{"name":5,"class":6},1]